On November 23, 2022, a Class II recall was initiated for Desmopressin Acetate Tablets, 0.2mg, in 100-count bottles. The recall, identified as D-0072-2023, was carried out by Heritage Pharmaceuticals Inc. The stated reason for the recall was that the product was subpotent. The recalled product was distributed by Avet Pharmaceuticals Inc., based in East Brunswick, NJ, under NDC 23155-490-01. The recall has been classified by the FDA as Class II. According to the available record, the status of this recall is listed as terminated. This recall pertains specifically to the identified lot or lots of desmopressin acetate tablets described in the notice, not to desmopressin as a compound generally. No additional details regarding the scope of affected lots or further corrective actions were provided in this record. Readers seeking more context on desmopressin, including its approved uses and regulatory status, can consult the compound overview for further information.
Desmopressin Acetate Tablets Recalled (Class II) Over Subpotency
Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.
See the full desmopressin overview
Source: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts